Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitor angioedema higher in Black patients
Safety · ACEARB-SAFE-03 · v2
Across many different kinds of studies, angioedema linked to ACE inhibitors shows up more often in Black patients than in white patients. A controlled enalapril trial found black race to be an independent risk factor [2], and large real-world patient databases found angioedema rates several times higher in Black patients [1],[17]. A heart-failure cohort, a case-control study and a UK routine-care study all pointed the same way [9],[10],[18]. The direction is the same everywhere and the size of the difference is large, which is why the panel treated the finding as well supported. Most of the evidence comes from observational records rather than head-to-head experiments, and some studies counted all angioedema hospitalisations rather than only drug-attributed cases, but the strongest estimates were specific to ACE inhibitors.
A prospective controlled enalapril trial identified black race as an independent risk factor for angioedema (OR 2.88, 95% CI 1.72-4.82) [2]. Large administrative cohorts found a roughly four-fold higher frequency in Black patients: adjusted RR 4.5 (95% CI 2.9-6.8) in a Tennessee Medicaid cohort [1] and nearly four-fold higher rates among 195,192 ACE initiators in US veterans [17]. A heart-failure database cohort reported incidence of 6.2 versus 2.9 per 1000 patient-years in Black versus non-black patients [9], a case-control study reported black race OR 2.25 (95% CI 1.86-2.72) [10], and a UK routine-care emulation found higher absolute angioedema risk in Black individuals [18]. Hospitalisation databases [6],[7],[8] and heart-failure trial adjudications [13],[25] add consistent directional support. The contested point: The clearest internal tension is that the case-control study found ACE-I use and black race were not synergistic (interaction OR 1.10, 95% CI 0.80-1.51) [10], so the two are independent rather than multiplicative risk factors. A second point is indirectness: some supporting papers counted all-cause angioedema hospitalisations rather than ACEi-attributed events [6],[7],[8], though the strongest estimates [1],[2],[9],[17],[18] are ACEi-specific.
All 27 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Most evidence is observational and subject to residual confounding (prescribing patterns, healthcare access, differential ascertainment), though the adjusted RCT [2] and multivariable cohorts mitigate this.
Several corpus papers ([6],[7],[8]) measure all-cause angioedema hospitalisation rather than ACEi-attributed events, introducing indirectness; however the strongest estimates ([1],[2],[9],[17],[18]) are ACEi-specific, so the claim is not reliant on the indirect ones.
Where it remains uncertain. The two strongest risk factors, ACE-I use and black race, were not synergistic (OR 1.10, 95% CI 0.80-1.51) [10], and part of the supporting corpus measures all-cause rather than ACEi-attributed angioedema [6],[7],[8].
Aleatory
Angioedema is uncommon (e.g. 86 cases in [2], 82 in [1], 20 in [20], 19 in [11]), so race-stratified estimates rest on few events and carry sampling variability, reflected in wide intervals such as 6.2 (95% CI 3.1-12.5) in [9].
Epistemic
Why risk is higher in Black patients is not established: bradykinin-sensitivity data [4] are suggestive, and GWAS found no large-effect or race-specific variant [5],[23], leaving the biological basis open.
The load-bearing papers from a corpus of 27, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Adjusted cohort estimate: ~4.5x higher risk in Black vs white ACE inhibitor users.
“the adjusted relative risk (RR) of angioedema among black American users of ACE inhibitors was 4.5 (95% confidence interval [CI] 2.9 to 6.8) compared with white subjects”
Panel auditInternal validity: medium · scope of inference: Tennessee Medicaid ACE inhibitor users aged ≥15, 1986–1992.Key limitations: retrospective administrative data · single-state Medicaid population · era-specific prescribing
Controlled trial identifies black race as an independent risk factor, OR 2.88.
“Stepwise logistic regression identified black race (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.72-4.82), history of drug rash (OR, 3.78; 95% CI, 1.80-7.92), age greater than 65 years (OR, 1.60; 95% CI, 1.02-2.53), and seasonal allergies (OR, 1.79; 95% CI, 1.06-3.00) as independent risk factors for angioedema”
Panel auditInternal validity: high · scope of inference: Hypertensive adults treated with enalapril 5–40 mg/d in a controlled trial.Key limitations: single-ACEi (enalapril) only · uncommon event limits precision
Real-world HF cohort: higher incidence in Black patients.
“The incidence was higher in Black [6.2 (95% CI 3.1-12.5)] than in non-black [2.9 (95% CI 2.1-4.1)] patients”
Panel auditInternal validity: medium · scope of inference: US heart-failure patients initiating an ACEI, 2007–2015 (claims data).Key limitations: overlapping CIs · claims-based outcome · no formal race test reported
Reports greater bradykinin wheal response in African Americans, a surrogate mechanism, not the frequency of ACEi-induced angioedema the claim asks about.
Panel auditInternal validity: medium · scope of inference: Salt-replete hypertensive and normotensive African Americans and Caucasians challenged with bradykinin.Key limitations: surrogate endpoint not angioedema · sample size not stated in abstract
4 of 27 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent primary studies, including a controlled trial and very large cohorts, converge on a large, consistent excess risk in Black patients with no credible contradicting primary evidence in the corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Causal versus ascertainment basis of the race difference. Observational records cannot separate a true excess from differential diagnosis, coding or access, which bears directly on whether the frequency difference is real or measurement-driven. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective multi-site study with uniform, blinded angioedema adjudication and standardised exposure follow-up across self-identified race groups.
Open question: How much of the higher measured angioedema frequency in Black patients is attributable to biology or exposure versus differential ascertainment and healthcare access? Why it is still open: The strongest estimates are observational [1],[9],[10],[17],[18] and the Sceptic flagged residual confounding that adjustment cannot fully remove.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 22 Oct 2026 · protocol v0.19